- Home
- MFIC vs IMTX Comparison
MFIC vs IMTX Comparison
Compare MFIC & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIC
- IMTX
- Stock Information
- Founded
- MFIC 2004
- IMTX N/A
- Country
- MFIC United States
- IMTX Germany
- Employees
- MFIC N/A
- IMTX N/A
- Industry
- MFIC Finance/Investors Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIC Finance
- IMTX Health Care
- Exchange
- MFIC Nasdaq
- IMTX Nasdaq
- Market Cap
- MFIC 1.1B
- IMTX 1.1B
- IPO Year
- MFIC 2004
- IMTX N/A
- Fundamental
- Price
- MFIC $13.69
- IMTX $12.99
- Analyst Decision
- MFIC Buy
- IMTX Strong Buy
- Analyst Count
- MFIC 8
- IMTX 2
- Target Price
- MFIC $14.79
- IMTX $16.00
- AVG Volume (30 Days)
- MFIC 386.3K
- IMTX 369.4K
- Earning Date
- MFIC 11-05-2024
- IMTX 11-12-2024
- Dividend Yield
- MFIC 10.92%
- IMTX N/A
- EPS Growth
- MFIC 52.81
- IMTX N/A
- EPS
- MFIC 1.71
- IMTX N/A
- Revenue
- MFIC $277,613,000.00
- IMTX $75,935,926.00
- Revenue This Year
- MFIC $11.72
- IMTX $42.78
- Revenue Next Year
- MFIC $15.40
- IMTX N/A
- P/E Ratio
- MFIC $8.07
- IMTX N/A
- Revenue Growth
- MFIC 7.35
- IMTX N/A
- 52 Week Low
- MFIC $12.26
- IMTX $7.15
- 52 Week High
- MFIC $16.36
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- MFIC 48.58
- IMTX 61.77
- Support Level
- MFIC $13.31
- IMTX $11.69
- Resistance Level
- MFIC $13.79
- IMTX $12.86
- Average True Range (ATR)
- MFIC 0.16
- IMTX 0.45
- MACD
- MFIC 0.02
- IMTX 0.17
- Stochastic Oscillator
- MFIC 68.12
- IMTX 82.27
About MFIC MidCap Financial Investment Corporation
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.